Skip to main content
. 2019 Jan 4;9:1470. doi: 10.3389/fphar.2018.01470

Table 1.

Basic Characteristics of the Included Studies.

Study ID Sex (M/F) AVG age N (E/C) TNM stages EST (m) KPS score Therapy of CHIs+radiotherapy group Therapy of radiotherapy group Treatment (days) Outcomes
Yang YM 2013 38/22 48 30/30 I–III ≥3 >60 AD 100 ml+ DT = 66Gy DT = 66Gy 30d ① ②
Fang H 2011 38/22 48 30/30 I–III ≥3 >60 AD 100 ml+ DT = 66Gy DT = 66Gy 30d ① ②
Zeng QB 2006 NR NR 72/72 NR NR NR AD 100 ml+ DT = 60–70Gy DT = 60–70Gy 15d × (2–3) ① ④
Mao HY 2016 80/30 65 55/55 NR ≥3 ≥60 AD 100 ml+ DT = 50–66Gy DT = 50–66Gy 30d ① ③
Zhao KY 2010 54/16 57 40/30 II–IV ≥5 >60 AD 50 ml+ DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ②
Guo YC 2014 56/40 57 ± 5 50/46 II–IV ≥6 ≥70 AD 50 ml+ DT = 60–66Gy DT = 60–66Gy 7d × (6–7) ① ③
Li MJ 2014 43/17 58 30/30 II–IV >6 ≥60 AD 50 ml+ DT = 60Gy DT = 60Gy 5d × 4 ① ③
Lu K 2006 56/29 56 43/42 II–III NR ≥70 AD 60 ml+ DT = 60–70Gy DT = 60–70Gy 21d ① ③
Hu LM 2010 42/26 58.4 34/34 NR NR ≥70 AD 50 ml+ DT = 64–70Gy DT = 64–70Gy 7d × (6–7) ③ ④
Bai LK 2014 33/16 75.4 25/24 NR NR >60 AD 50 ml+ DT = 50–70 Gy DT = 50–70 Gy 7d × (4–7) ③ ④
Zhao X 2015 40/32 NR 36/36 NR ≥6 ≥70 AD 50 ml+ DT = 64Gy DT = 64Gy 7d × (6–7) ③ ④
Han JW 2008 NR 71.5 48/47 II–IV NR ≥70 AD 50 ml+ DT = 65–70Gy DT = 65–70Gy 7d × (6–7) ① ③
Xing HJ 2011 46/34 70.5 40/40 NR >3 ≥70 AD50 ml+ DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ② ③ ④
Wu YH 2001 NR NR 48/48 NR NR >60 AD 30–50 ml+ DT = 68–70Gy DT = 68–70Gy 7d × (6–7) ① ③ ④
Liu XP 2006 36/12 75 24/24 NR NR ≥60 AD 60 ml+ DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ② ③
Jiang SN 2010 36/14 64.5 26/24 NR NR 70–90 DC 0.5–1.0 mg+ DT = 60Gy DT = 60Gy 7d × 6
Zhou M 2009 44/19 51.5 32/31 NR NR ≥70 SM 50 ml+ DT = 60Gy DT = 60Gy 10d × 3 ① ③ ④
Zhu GJ 2013 NR NR 30/30 NR NR 60–80 SQFZ 250 ml+ DT = 64Gy DT = 64Gy 28d ③ ④
Cai P 2006 98/28 NR 53/73 NR NR >60 CKS 20 ml+ DT = 66–74Gy DT = 66–74Gy 20d ③ ④
Yan L 2015 45/35 55 40/40 I–IV NR ≥70 CKS 20 ml+ DT = 60–66Gy DT = 60–66Gy 14d ② ③
Sun TZ 2009 53/17 55.5 35/35 NR NR >60 CKS 20 ml+ DT = 60–70Gy DT = 60–70Gy 21d ③ ④
Huang CH2016 49/31 70–80 40/40 NR NR ≥70 CKS 15–20 ml+DT = 60–66Gy DT = 60–66Gy 7d × (6–7) ③ ④
Ao JF 2006 21/11 56.8 18/14 III–IV NR ≥60 CKS 20 ml+ DT = 60–70Gy DT = 60–70Gy 7d × (4–6) ① ③
Chen XY 2006 54/13 55 33/35 NR NR ≥60 CKS20–40 ml+DT = 66.6–67Gy DT = 66.6–67Gy 10d × (3–4) ① ② ③ ④
Sheng ZJ 2009 67/61 72.2 66/62 III NR NR CKS 20 ml+ DT = 60Gy DT = 60Gy (14–35)d ② ③
Ding JQ 2011 23/25 55.2 24/24 NR NR ≥70 CKS 20 ml+ DT = 65.4–67Gy DT = 65.4–67Gy 20d ② ③ ④
Li Z 2012 48/19 63 35/32 II–III >3 >60 CKS 15 ml+ DT = 60–66Gy DT = 60–66Gy 14d × (2–3) ① ② ③
Luo M 2013 NR NR 26/23 NR >3 >70 CKS 25 ml+ DT = 50–66Gy DT = 50–66Gy 7d × (5–7)
Liu FX 2009 66/34 53.2 50/50 NR NR ≥60 CKS 20 ml+ DT = 54–66Gy DT = 54–66Gy (14–21)d
Zhou DA 2002 116/44 61.9 80/80 NR NR ≥70 HCS 20 mL+ DT = 60–70Gy DT = 60–70Gy 28d
Tian SP 2013 12/10 72–89 10/12 NR >6 >70 CHS 20 mL+ DT = 60Gy DT = 60Gy 7d × 6
Zhang FT 2001 32/28 55 30/30 NR >3 >70 CHS 40 mL+ DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ④
Wang ZM 2010 34/22 68 28/28 NR NR ≥70 CHS20–30 mL+DT = 40–50Gy DT = 40–50Gy (21–28)d ① ② ③
He WX 2007 38/22 48 30/30 I–III ≥3 >60 AP 250 ml+ DT = 66Gy DT = 66Gy 2ld ① ②
Fan T 2012 NR NR 60/60 NR NR ≥60 AI 30 ml+ DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ③
An SH 2008 35/5 71 20/20 NR NR NR KA 40 ml+ DT = 60–64Gy DT = 60–64Gy 7d × (6–7)
Zhao DL 2006 38/22 48 30/30 I–III NR NR KA 60 ml+ DT = 66Gy DT = 66Gy 7d × (6–7) ① ②
Wang WH2014 49/29 55.9 39/39 III–IV ≥3 ≥70 KA 60 ml+ DT = 50–70Gy DT = 50–70Gy 28d × 2 ① ③
Mu Y 2012 32/18 54 25/25 NR NR ≥70 KA 60 ml+ DT = 60–70Gy DT = 60–70Gy 7d × 6 ① ②
Zhang HF 2014 39/11 61 25/25 NR NR NR KA 50 ml+ DT = 60–66Gy DT = 60–66Gy 7d × (6–7) ① ③
Wu ZP 2013 56/31 72.3 43/44 NR >3 >60 KA 60 ml+ DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ② ③ ④
Ren MZ 2013 39/15 NR 28/26 NR NR ≥60 KA 40–60 ml+ DT = 60Gy DT = 60Gy 30d × 2 ① ③
Ding H2013 59/21 58.5 40/40 NR NR ≥80 EL 200 mg+ DT = 50–60Gy DT = 50–60Gy 7d × (6–7) ① ③
Zhu XG 2016 51/41 67.6 50/42 II–III NR NR EL 600 mg+ DT = 50–60Gy DT = 50–60Gy 30d × 2 ① ③ ④
Wu J 2011 37/23 56 30/30 NR >3 >70 LE lmg+ DT≥ 45Gy DT≥45Gy 7d × 6 ① ② ③
Feng SJ 2015 35/25 65.5 30/30 NR NR NR JOE 30 ml+ DT = 60Gy DT = 60Gy 21d × 3 ① ③
Li DZ 2011 37/19 53 28/28 NR NR ≥70 JOE 30 ml+ DT = 50–60Gy DT = 50–60Gy 21d ① ④
Li Q 2013 36/14 62 25/25 NR >12 ≥70 JOE 30 ml+ DT = 60Gy DT = 60Gy 7d × 6 ① ④
Jia YS 2008 116/32 55.6 76/72 NR NR ≥70 JOE 30–50 ml+ DT = 60–68Gy DT = 60–68Gy 30d ② ③ ④
Chen SD 2007 65/27 NR 44/48 NR NR ≥70 JOE 10–20 ml+ DT = 64–70Gy DT = 64–70Gy 7d × (6–7)
Jiang XC 2009 41/28 55.6 35/34 NR NR ≥70 JOE 30 ml+ DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ③
Kong XM 2004 47/13 55.6 30/30 NR NR >60 JOE 30 ml+ DT = 60–70Gy DT = 60–70Gy 21d × 2 ① ③ ④
Liu XX 2010 39/17 61 28/28 NR NR 60–80 JOE 30 ml+ DT = 60–70Gy DT = 60–70Gy 21d × 2 ① ③
He LJ 2010 63/7 63 35/35 NR NR ≥60 JOE 30 ml + DT = 60–70Gy DT = 60–70Gy 7d × (6–7) ① ③
Qi JH 2015 68/42 61.8 61/49 NR NR ≥60 JOE 20–30 ml+ DT = 60–66Gy DT = 60–66Gy 7d × (6–7) ① ②

M, male; F, female; E, experimental group; C, control group; NR, not reported; EST, expected survival time; m, month; d, day; c, cycle; ①, clinical effectiveness rate; ②, performance status, ③, ADRs; ④, survival rate; AD, Aidi injection; AI, Astragalus injection; AP, Astragalus polysaccharide injection; CKS, Compound kushen injection; DC, Disodium cantharidinate and vitamin B6 injection; EL, Elemene injection; HCS, Huachansu injection; JOE, Javanica oil emulsion injection; KA, Kangai injection; LE, Lentinan injection; SM, Shenmai injection; SQFZ, Shenqifuzheng injection; DT, radiation absorbed dose.